The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Aberrant Regulation of Survivin by the RB/E2F Family of Proteins
Open accessAbstract
Survivin is a putative oncogene that is aberrantly expressed in cancer cells. It has been hypothesized to play a central role in cancer progression and resistance to therapy in diverse tumor types. Although some of the transcriptional processes regulating its expression have been established, the diversity of genes that may be controlling the levels of its expression in both normal cells as well as in cancer cells has not been fully explored. The most common genetically mutated pathways in human malignancies are the p53 tumor suppressor pathway and the RB/E2F pathway. Both of these pathways, when intact, provide essential checkpoints in the maintenance of normal cell growth and protect the cell from DNA damage. Using non-transformed embryonic fibroblasts, we provide evidence of a molecular link between the regulation of survivin transcription and the RB/E2F family of proteins. We demonstrate that both pRB and p130 can interact with the survivin promoter and can repress survivin transcription. We also show that the E2F activators (E2F1, E2F2, and E2F3) can bind to the survivin promoter and induce survivin transcription. Genetically modified cells that harbor deletions in various members of the RB/E2F family confirm our data from the wild-type cells. Our findings implicate several members of the RB/E2F pathway in an intricate mechanism of survivin gene regulation that, when genetically altered during the process of tumorigenesis, may function within cancer cells to aberrantly alter survivin levels and enhance tumor progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690
Sibling rivalry in the E2F family
Trimarchi, J. M., & Lees, J. A. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm714 · Cited by 1,158
The retinoblastoma tumour suppressor in development and cancer
Classon, M., & Harlow, E. (2002) · Nature Reviews Cancer · doi:10.1038/nrc950 · Cited by 738
Targeted disruption of the three Rb-related genes leads to loss of G 1 control and immortalization
Sage, J., Mulligan, G. J., Attardi, L. D., Miller, A., Chen, S., Williams, B., Theodorou, E., & Jacks, T. (2000) · Genes & Development · doi:10.1101/gad.843200 · Cited by 582
p21/CDKN1A Mediates Negative Regulation of Transcription by p53
Löhr, K., Möritz, C., Contente, A., & Dobbelstein, M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m212517200 · Cited by 227
p130/E2F4 Binds to and Represses the cdc2 Promoter in Response to p53
Taylor, W. R., Schönthal, A. H., Galante, J., & Stark, G. R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m005101200 · Cited by 110
Cited by
Survivin, cancer networks and pathway-directed drug discovery
Altieri, D. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2293 · Cited by 994
Resveratrol as an anticancer nutrient: molecular basis, open questions and promises
Signorelli, P., & Ghidoni, R. (2005) · The Journal of Nutritional Biochemistry · doi:10.1016/j.jnutbio.2005.01.017 · Cited by 489
Survivin, a cancer target with an emerging role in normal adult tissues
Fukuda, S., & Pelus, L. M. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-05-0375 · Cited by 465
Structural, functional and therapeutic biology of survivin
Sah, N. K., Khan, Z., Khan, G. J., & Bisen, P. S. (2006) · Cancer Letters · doi:10.1016/j.canlet.2006.03.007 · Cited by 355
Survivin: A molecular biomarker in cancer
Mittal, R., Jaiswal, P., & Goel, A. (2015) · Indian Journal of Medical Research · doi:10.4103/0971-5916.159250 · Cited by 352
Metadata
- Authors
- Jiang, Y., Saavedra, H. I., Holloway, M. P., Leone, G., & Altura, R. A.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2004-09
- Volume
- 279
- Issue
- 39
- Pages
- 40511-40520
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2058570034
- Cited by
- 160
- References
- 7
- FWCI
- 6.46
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.